Page last updated: 2024-12-05
stanolone benzoate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
stanolone benzoate: RN given refers to (5alpha,17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 13987 |
| CHEBI ID | 34979 |
| SCHEMBL ID | 3366936 |
| MeSH ID | M0119611 |
Synonyms (45)
| Synonym |
|---|
| unii-t74307g2d9 |
| 4-09-00-00464 (beilstein handbook reference) |
| t74307g2d9 , |
| 5alpha-androstan-3-one, 17beta-hydroxy-, benzoate |
| androstan-3-one, 17-(benzoyloxy)-, (5alpha,17beta)- |
| (5-alpha,17-beta)-17-(benzoyloxy)androstan-3-one |
| 5-alpha-androstan-3-one, 17-beta-hydroxy-, benzoate |
| 5alpha-dihydrotestosterone benzoate |
| 5-alpha-17-beta-hydroxyandrostan-3-one benzoate |
| brn 3122672 |
| nsc 69549 |
| einecs 213-891-8 |
| androstan-3-one, 17-(benzoyloxy)-, (5-alpha,17-beta)- |
| 5-alpha-dihydrotestosterone benzoate |
| nsc69549 |
| androstanolone benzoate |
| dihydrotestosterone benzoate |
| sarcosan |
| hermalone |
| nsc-69549 |
| 1057-07-4 |
| 5.alpha.-androstan-3-one, benzoate |
| 5.alpha.-dihydrotestosterone benzoate |
| stanolone benzoate |
| [(5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] benzoate |
| SCHEMBL3366936 |
| androstanolone 17-benzoate |
| vetranal |
| AKOS015889514 |
| 5.alpha.-androstan-3-one, 17.beta.-hydroxy-, benzoate |
| CHEBI:34979 |
| androstan-3-one, 17-(benzoyloxy)-, (5.alpha.,17.beta.)- |
| (5.alpha.,17.beta.)-3-oxoandrostan-17-yl benzoate |
| ZGDZDAPCWHIIKB-LVYWIKMTSA-N |
| androstanolone benzoate;dihydrotestosterone benzoate;dhtb |
| DTXSID0036502 |
| androstanolone 17-benzoate, vetranal(tm), analytical standard |
| 5alpha-androstan-17beta-ol-3-one benzoate |
| 1,6,7,12-tetrachloroperylenetetracarboxylic aciddianhydride |
| Q27116348 |
| HY-128698 |
| (8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxohexadecahydro-1h-cyclopenta[a]phenanthren-17-yl benzoate |
| dhtb |
| CS-0098596 |
| PD126040 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| steroid ester | |
| 3-oxo-5alpha-steroid | A 3-oxo steroid that has alpha configuration at position 5. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.44) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||